NCT07218380 2026-04-17
FORAGER-2
Eli Lilly and Company
Phase 3 Recruiting
Clinical Trials
6 trialsNCT06524544 2026-04-15
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT05911295 2026-04-07
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Seagen Inc.
Phase 3 Active not recruiting
NCT04637594 2026-03-20
IMAGINE
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT03898180 2026-02-05
LEAP-011
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03374488 2025-08-22
Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
Incyte Corporation
Phase 3 Completed